Analysts See $-0.05 EPS for Biomerica, Inc. (BMRA); Intuit Has 0.9 Sentiment

March 25, 2018 - By Hugh Holland

Analysts expect Biomerica, Inc. (NASDAQ:BMRA) to report $-0.05 EPS on April, 13.They anticipate $0.01 EPS change or 25.00% from last quarter’s $-0.04 EPS. After having $-0.03 EPS previously, Biomerica, Inc.’s analysts see 66.67% EPS growth. It closed at $4.21 lastly. It is down 66.46% since March 25, 2017 and is uptrending. It has outperformed by 49.76% the S&P500.

Intuit Inc. provides financial management and compliance services and products for small businesses, consumers, self-employed, and accounting professionals in the United States and internationally. The company has market cap of $43.51 billion. The companyÂ’s Small Business segment provides small business payroll services and products, including QuickBooks Desktop software products, such as Desktop Pro, Desktop for Mac, Desktop Premier, and Enterprise; QuickBooks Basic Payroll and QuickBooks Enhanced Payroll; QuickBooks Point of Sale solutions; ProAdvisor Program memberships for accounting professionals; and financial supplies. It has a 46.55 P/E ratio. This segment also offers QuickBooks Online, and QuickBooks Self-Employed financial and business management offerings; QuickBooks Enterprise term licenses and QuickBooks technical support plans; small business payroll services, including QuickBooks Online Payroll, Intuit Online Payroll, QuickBooks Assisted Payroll, and Intuit Full Service Payroll; and payment processing services for small businesses.

Ratings analysis reveals 50% of Intuit’s analysts are positive. Out of 4 Wall Street analysts rating Intuit, 2 give it “Buy”, 1 “Sell” rating, while 1 recommend “Hold”. The lowest target is $108.0 while the high is $130.0. The stock’s average target of $119 is -29.95% below today’s ($169.87) share price. INTU was included in 4 notes of analysts from August 24, 2016. The firm has “Outperform” rating by Credit Suisse given on Friday, February 24. On Tuesday, September 13 the stock rating was downgraded by Morgan Stanley to “Underweight”. Deutsche Bank maintained Intuit Inc. (NASDAQ:INTU) on Wednesday, August 24 with “Buy” rating. RBC Capital Markets maintained it with “Sector Perform” rating and $108.0 target in Wednesday, August 24 report.

Since January 1, 0001, it had 0 insider buys, and 8 selling transactions for $190.62 million activity.

The stock decreased 2.84% or $4.96 during the last trading session, reaching $169.87. About 1.75 million shares traded or 27.01% up from the average. Intuit Inc. (INTU) has risen 23.62% since March 25, 2017 and is uptrending. It has outperformed by 6.92% the S&P500.

Analysts await Intuit Inc. (NASDAQ:INTU) to report earnings on May, 22. They expect $4.33 EPS, up 16.71% or $0.62 from last year’s $3.71 per share. INTU’s profit will be $1.11B for 9.81 P/E if the $4.33 EPS becomes a reality. After $0.08 actual EPS reported by Intuit Inc. for the previous quarter, Wall Street now forecasts 5,312.50% EPS growth.

Lindsell Train Ltd holds 11.34% of its portfolio in Intuit Inc. for 2.37 million shares. Mar Vista Investment Partners Llc owns 663,547 shares or 3.92% of their US portfolio. Moreover, Disciplined Growth Investors Inc Mn has 3.8% invested in the company for 1.28 million shares. The Connecticut-based Baxter Bros Inc has invested 3.65% in the stock. Account Management Llc, a Massachusetts-based fund reported 26,449 shares.

Since January 23, 2018, it had 4 insider purchases, and 0 insider sales for $65,333 activity. Irani Zackary S. bought $3,960 worth of Biomerica, Inc. (NASDAQ:BMRA) on Friday, February 2. $49,324 worth of Biomerica, Inc. (NASDAQ:BMRA) was bought by CANO FRANCIS on Wednesday, January 24.

Investors sentiment increased to 1 in Q3 2017. Its up 0.75, from 0.25 in 2017Q2. It improved, as 2 investors sold Biomerica, Inc. shares while 2 reduced holdings. 1 funds opened positions while 0 raised stakes. 66,682 shares or 11.38% less from 75,249 shares in 2017Q2 were reported. Wells Fargo & Mn owns 6,500 shares or 0% of their US portfolio. North Star Management holds 250 shares. Millennium reported 27,023 shares. Malaga Cove Ltd invested in 19,000 shares. Comml Bank Of America Corp De invested 0% in Biomerica, Inc. (NASDAQ:BMRA). Moreover, Panagora Asset Management has 0% invested in Biomerica, Inc. (NASDAQ:BMRA) for 10,077 shares.

Biomerica, Inc., together with its subsidiaries, develops, makes, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions worldwide. The company has market cap of $35.96 million. The companyÂ’s diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; and to measure the level of specific hormones, antibodies, antigens, or other substances, which exist in the human body in extremely small concentrations. It currently has negative earnings. It primarily focuses on products for gastrointestinal, food intolerances, diabetes, and esoteric tests.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News